U.S. Markets closed

Navidea Biopharmaceuticals, Inc (NAVB)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.50-0.04 (-6.59%)
At close: 4:11PM EDT
People also watch
IMUCMSTXCLSNGALECPRX
Full screen
Previous Close0.54
Open0.55
Bid0.00 x
Ask0.00 x
Day's Range0.50 - 0.55
52 Week Range0.26 - 1.16
Volume537,332
Avg. Volume428,112
Market Cap80.85M
Beta-0.97
PE Ratio (TTM)1.05
EPS (TTM)0.48
Earnings DateMar 24, 2017 - Mar 27, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    Navidea Enters Exclusive License and Distribution Agreement For India with Sayre Therapeutics

    Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it has entered into an exclusive license and distribution agreement with Sayre Therapeutics for the development and commercialization of Tc 99m tilmanocept in India.

  • American City Business Journals13 days ago

    Navidea getting new revenue source as cancer diagnostic aid launches in Europe

    Navidea Biopharmaceuticals Inc. gets a new source of sales revenue with the European launch of the drug for which it sold North American rights in spring. SpePharm AG, a specialty pharmaceutical arm of Dutch distributor Norgine BV, started sales of Lymphoseek in the United Kingdom, Denmark and the Netherlands. SpePharm's exclusive sub-license applies to all 28 current EU member countries, and it is working to start sales in the rest.

  • Business Wire13 days ago

    Navidea’s Commercial Partner, Norgine B.V., Launches LYMPHOSEEK® in Europe

    Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that its European commercial partner, SpePharm AG, an affiliate of Norgine, B.V., launched LYMPHOSEEK® , originally developed by Navidea, in Denmark, the Netherlands and the UK.